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Aprotinin and Hemostasis
in Gardiopulmonary ByPass
routine cardiac surgery by using the protease inhibitor aprotinin.
The use of CPB causes massive contact-phase and complement activation as
complement system. As specific assays to determine the effect of blood activation
during CPB on the different pathways are now available, insight into systemic
bloodactivation, particularly into the major factors leading to impaired hemostasis
and the effects of aprotinin during CPB, has increased,
Hemostatic Mechanisms at the Bleeding Sites
during Surgery
Upon incision and thus the cutting of blood vessels, platelets immediately adhere
onto rhe de-endotheliaiized vascular wall structures, such as coilagen fibers,
basement membranes, and microfibrils, This prompt reaction is caused by various
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accessible giycoprotein receptors on platelets for von Willebrand factor (vWF),
collagen, uttd lamini.t. For instance, glycoprotein (GP) Ib receptors on the platelet
membrane bind to collagen fibrils via tissue-bound vWF.
At the same time, tissue factor activates the extrinsic coagulation pathway,
thrombin sparks thrombin generation explosively.
The aciivation of platelets is also followed by a change in the shape of platelets
(i.e., pseudopod formation) and microvesicle shedding, which enlarges the procoag-
ulant surfaces, contributing to the explosive increase of thrombin generation,
Thrombin also induces a release of the platelets'granule contents. which play a role
in locai hemostatis, Adenosine diphosphate (ADP), released from the dense bodies,
stimulates plateleC aggregation" whereas serotonin, released from the grarules,
causes local vasoconstriction.
Thrombin that is generated within the piatelet plug, polymerizej fibrinogen
into fibrin, which leads to the formation of a more solid, hemostatic plug. At the
site of an arteriai lesion, Iocal thrombin generation should be explosive. If not,
thrombin would be washed-out by the fast blood flow. However, explosive thrombin
generation should only Iead to local hemostatic plug formation, not to disseminated
intravascular coagulation, Therefore, the positive feedback activation of cofactors
(factors Va and VIIIa) should be counteracted by activation of negative feedback
systems. This is effectuated by tissue factor plasma inactivator (TFPI) and anti'
thrombin III but particularly by the protein C and protein S systems. The protein C
system is activated by the binding of thrombin to the receptor thrombomodulin on
the surface of endothelial cells. During this process, thrombin loses its procoagulant
properties. In conjunction with protein S and the phospholipid piatelet membrane,
lctivated protein C inactivates Va and VIIIa into Vi and VIIIi, thereby ending further
prothrombin conversion.
When thrombin is generated systemically, the level of activated protein C
increases before any change in the level of factor V fibrinogen, or platelets can be
observed, This regulation of protein C seems to play a pivotal role in preventing
disseminated intravascular coagulation.
In addition, by neutralizing the inhibitor of the tissue-type plasminogen
activator (PAI), activated protein C stimulates fibrinolysis. Fibrinolysis, i.e., the
splitting of polymerized fibrin strands, is caused by the proteolytic enzyrne plas-
min. Plasmin arises from plasminogen, a process that is induced by plasminogen
acrivators uch as rissue-tlpe plasminogen activator (tPA). The release of tPA from
endothelial cells is stimulated by various factors that also activate clotting.
Atthough tPA by itself is a poor plasminogen activator, counteracted in plasma
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by plasnrinogen-acrivaror inhibitors l ike PAI-l, i ts activity increases hundredfold
iri the presence of f ibrin. This explains why tPA is primariiy effective in hemo-
stat ic  p lugs.
When tpA is present, f ibrin monomers on the platelet surface accelerate local
plasminogen activation to form plasmin, which internalizes the GPIb receptors on
platelets., This might help to prevent circulating platelets from continuing to
udhere and participate in the init ial, Iocai hemostatic process. In addition to
plateiet activation that stops the positive feedback activation of thrombin by
receptors on the platelets' surface. This binding causes the transmembrane calcium
channels to open, Icading to an influx of calcium into the platelets. This calcium
ilf lux activares processes that lead to a functional change of GPIIb-IIIa, enabling its
opposes the shear-stress that f lowing blood exerts on the platelet plug formation. In
contrast ro thrombin-induced platelet aggregatio& shear-induced platelet aggregation
is independent of the cyclo-oxygenase pathwaylT and, therefore, not inhibited by
aspirin.
When platelets in flowing blood are not activated and shear-forces are low,
platelets can adhere to and spread on a surface in case the GPIb platelet receptors
;'recognize" immobilized vWF. In addition, GPIIb-iIIa receptors can bind to-fibrino'
gen, and cohesion with other platelets can proceed. These processes can occur
even when piatelets are inhibited by aspirin. However, when GPlb binds to
immobilized vWF or soluble vWF (at higher shear-rates), or when thrombin binds
to thrombin receptors independent of shear-forces, platelets do become activated.
Both strong piatelet adherence and platelet aggregation to oppose high shear-forces
are particularly effectuated by activated GPIIb-IiIa receptors binding to multi-
meric vWF,
It is clear that the Iocai circumstances at the site of vascular damage determine
effective hemostatic plug formation, which primarily depends on platelet adhesion
and aggregation, It is important to realize that two platelet mechanisrns contribute
ro hemostasis: the l igand- (thrombin)-induced platelet activation and the shear-
induced platelet activation. The first depends on tl le cyclo-oxygenase pathway; the
second does not .
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Factors Affecting Hemostasis
in Gardiopulmonary Bypass
Increasing numbers of patients presenting for coronary artery bypass grafting-are
treated viith aspirin. Therefore, hemostasis may already be impaired- before
surgery, as desciibed in the preceeding discussion. In this regard. a prophylactic
dosi oi 100 mg of aspirin does not seem to affect hemostasis additionally in CPB,
small extent.
As mentioned earlier, the use of CPB leads to massive contact-phase and
complement activation, as blood interacts with the nonphysiolo,gical surfaces of
the Clpg circuit. This leads to activation of the intrinsic pathway of the coagulation
and fibrinolytic systems and subsequent thrombin and plasmin generation (Fig' i)'
Thrombin and plasmin are agonists with a high affinity for binding to the platelet
surface, thereby affecting the GPIb receptor (Fig. 2) and, thus, the platelet's hemo'
static function,l
Moreover, at various points of the CPB circuit, high shear'forces are, generated,
which activate platelets to adhere strongly to thrombogenic surfaces and aggregate.
T6is reduces the number of circulating platelets. In addition, high shear-forces
clamage rythrocytes, resulting in release of adenosine diphosphate (ADP). ADP is
an adf,itional strong agonist for platelet aggregation and further affects the hemo-
static capacity of platelets.
FIGURE 1. B-beto15-a2,  sPecific
marker for disseminated Intravascu-
lar coagulatlon (systemlc thrombin
generation), expressed as a percent-
age of init ial values, Increased con-
t inuously dur ing CPB.
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FIGURE 2. Platelet glycoprotein
receptor lb (GPlb), expressed as a
percentage of pre-CPB values, de-
creased by 4Oo/o at the onset of CPB.
Another source of blood activation that affects hemostasis during CPB is the
translocadon of endotoxin from the gut into the circulation.s,l0 This process is likely
to be associated with the disturbed microcirculation of the gut mucosa during CPB'
Under normal circumstances, the gut mucosa acts as an active barrier to prevent
translocation of endotoxin. Endotoxin causes contact activadon. stimulates mono-
cytes and macrophages to produce cytokines, and strongly activate endothelial cells
to release tPA, all of which interfere with the mechanisms involved in hemostasis.
Systemic blood activation is also caused by the recirculation of pericardially
shed blood via cardiotomy suction. This blood has been in extensive contact with
tissue, which particularly leads to activation of the extrinsic pathways of coagulation
platelet hemostatic function.2e
The above factors make it clear that platelet hemostatic function and capacity
are affected and fibrinolysis is activated during CPB due to multiple factors' These
factors together cause impaired hemostasis after CPB. Of importance also is that
the enzymatic activity of antiproteases, physiologically counteracting the activation
of the described plasmatic systems, becomes inhibited by hlpothermia, routinely
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interaction of heparin with vWF, eliminating the interference of heparin with
platelet hemostatic function.t: In addition, aprotinin in synergism with heparin
strongly inhibits the activation of the intrinsic coagulation pathway (Fig. 3) that is
due to contact activation by blood-material interaction and/or endotoxin transloca-
rion.r Moreover, aprotinin is an effective inhibitor of plasmin. Effective inhibition
of thrombin and plasmin by aprotinin leads to preservation of platelet GPIb recep-
tors (Fig. 4).6'27'28'12 This importantly contributes to maintain hemostasis (Fig' 5)'
The strong inhibition of fibrinolys-is enhances this effect even more.16
The mechanism by which protamine affects platelet function is unclear, and
studies on the effect of aprotinin in this regard are needed. Interestingly, improved
hemostasis by aprotinin administration can also be achieved in patients using
prophylactic aspirin (Figs. 6 and 71.22'zs An explanation of this effect is that shear-
induced platelet reactivity, which is independent of the cyclo-oxygenase pathway,
could be preserved by aprotinin, This emphasizes the essential role of tNs mechanism
in platelet plug formation at multiple bleeding sites during surgery.2o
Shear-induced platelet reactivity can be measured by doing a Thrombostat
tesr.rs This is an in vitro bleeding test, perfusing whole blood through an artificial
arteriole (ID 190 prm) under constant pressure (40 mm Hg). This generates a shear-
stress of I28 dyn/cmz, which can be compared with the value estimated at the
surgical bleeding site. By the induced shear-stress, platelets are activated and stick
to the collagen filter at rhe end of the capillary, thus forming a platelet hemostatic
plug. it is important to add ADP onto the filter to prevent an abnormally prolonged
test resulr being obtained in patients treated with aspirin.ra The binding of released
platelet-vWF induced by ADP seems to play a dominant role in platelet plug
formation by this specific shear-rate, which is not affected by aspirin.rz
Although the results of the in vivo bleeding test correlate with the in vitro
bleeding test,ts the in vivo test is more sensitive for detecting the various factors
influencing hemostasis.le For example, the clotting system and the cyclo-oxygenase
pathway tend to affect the in vivo 1s511e,30 Furthermore, CPB influences the in vivo
FIGURE 3. Generatlon of the
B-beta1512 fragment, the molec-
ular marker for dlssemlnated in-
travascular coagulatlon, was
completely inhibited by aprotinln
admlnistratlon (6mill lon KIU).
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FIGURE 4. Platelet glycoproteln receptor lB (GPlb) changes during CPB, expressed as a
percentage of pre-CPB values In aprotinln4reated patlents given only 2 mill ion KIU In the pump
prime or comlrlned wlth an addltional bolus of 2 mill ion KIU glven at inductlon of anesthesla and
a contlnuous Infusion of 2 mill ion KIU untl l protamlne administratlon (totat, 6 mill lon KIU) or pla-
cebo. GPlb receptors remalned preserved with aprotinin independent of the dose during CPB.
tesL depending on various factors, e.g., skin temperature, vasotonic medication, and
blood pressure.26 Therefore, the in vitro test during CPB is more specifically useful
for monitoring the shear-induced pathway of platelets, which seems to play a major
role in hemostasis, particularly in aspirin-treated patients.
In a recent study, we demonstrated the alteration in hemostasis induced by the
shear-induced platelet activation during CPB in aspirin-treated and non-aspirin-
treated patients. Before CPB, the bleeding volume during the Thrombostat test was
equal for both groups. Systemic heparinization influenced these test results only
FIGURE 5. Blood loss, ex-
pressed In grams of hemoglobln
content (S Hb), during and after
operation in patients treated with
6 mi l l lon KIU and 2 mi l l ion KIU
of aprotlnin was equally reduced
and s igni f icant ly  ( -p < 0.05)
lower than in patients receiving
olacebo.
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slightly, which signals that the effect of the clotting system is only minor.2a After
starting CPB, bleeding volume in both groups increased abruptly. This indicates
that the hemostatic capacity of platelets rapidly and strongly diminishes. During
CPB, however, the hemostatic capacity of the platelets was significantly more
affected in the aspirin-treated patients than in the non-aspirin-treated patients.
The reported, initial decrease of platelet membrane glycoprotein antigens (GPIb)
during CP827J2 might partly reflect the loss of the hemostatic capacity of platelets
during the Thrombostat est. In both groups, the shear-induced platelet aggregation
recovered parrly afrer CPB, but the hemostatic capacity of the platelets remained
significantly more affected in aspirin-treated patients than in placebo-treated
patients. This higher vulnerability of aspirin-treated patients for impaired hemostasis
induced by CPB, however, can be modified by aprotinin administration.22'25
FIGURE 6. Platelet glycoPro-
teln receptor (GPlb) was slgnlfl-
cantly (.p < 0.05) reduced at the
onset or QPB in non-aprotinln-
treated patients independent of
aspirin pretreatment. AProtinln
adminls t rat ion (2 mi l l ion KIU in
the pump prime), both In Patients
with or without aspirin pretreat-
ment, preserved platelet GPlb re-
ceptors during CPB.
FIGUHE 7. Postoperative blood
loss during 24 hours after oPera-
tion. Aprotinin slgnlflcantly de-
creased blood loss in aspirln-
treated and non-aspirin-treated
patients (-p < 0.05 comParing
aspirin-treated patients wlth as-
pi rin/aprotinin-treated patients;
.-p ( 0.05 comparlng non-treated
pat ients and aprot ln ln- t reated
patients).
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circurnstances that can influence hemostasis.
effects of aprotinin and it certainly reduces the costs'
With aii this in mind, it is important to realize that efforts to improve
hemostasis during CPB are primarily aimed at reducing or, if possible, eliminating
the need for blood products because of their inherent risks. To achieve this goal,
several cardiac centers have instituted a strict blood salvage protocol, which
ipcludes postoperative retransfusion of preoperatively donated autologous blood'
Also in this siruation, a iow dose of aprotinin shouid be considered, because it can
contribute substantially to reducing the use of blood products,2r On the other hand.
when postoperative retransfusion ofpreoperatively donated autologous blood Ieads
to the presirvation of a substantial number of platelets that do not endure the
negative effects of blood activation caused by CPB, the protective effect of 2 mill ion
I{U of aprotinin on circulating piatelets might not be so impressive anymore'
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However, potentiating effects are seen when heparin-coated circuits, the use of
which reduces complement activation,e are primed with 2 million I(IU of aprotinin.
In a recent study,r5 none of the separate variables, i.e,, neither heparin coating
nor aprotinin, improved hemostasis, but their combination did. Another observation
in this study was that the inflammatory reaction, which determines length of stay
in the intensive care unit, was also significantly milder following the combined use
reduce blood activation and limit the use of blood products should also be taken
when employing CPB.
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